← Browse by Condition

Medical Condition

nsclc

Total Trials

15

Recruiting Now

15

Trial Phases

Phase 1, Phase 1, Phase 2, Phase 2

ClinicalMetric tracks all active clinical trials for nsclc sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — nsclc Clinical Trials

How many clinical trials are currently recruiting for nsclc?

ClinicalMetric currently tracks 15 actively recruiting clinical trials for nsclc, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 15. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for nsclc?

nsclc research spans Phase 1 (6 trials), Phase 2 (5 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a nsclc clinical trial?

Eligibility criteria for nsclc trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

6

Phase 2

5

Top Sponsors

Wen-zhao ZHONG 1 trial

TORL Biotherapeutics, LLC 1 trial

Jun Zhang, MD, PhD 1 trial

Ellipses Pharma 1 trial

Peking University Cancer Hospital & Institute 1 trial

Recruiting Clinical Trials

Sub-lobectomy vs Lobectomy in IIA-IIIB NSCLC After Neoadjuvant IO+Chemo

NCT05103683 Phase 1

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

United States, South...

TORL Biotherapeutics, LLC

Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC

Jun Zhang, MD, PhD

NCT05443126 Phase 1, Phase 2

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

United States, Franc...

Ellipses Pharma

Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD

Peking University Cancer Hospi...

NCT07264673 Phase 2

A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.

Fondazione Ricerca Traslaziona...

APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch

Fondazione IRCCS Istituto Nazi...

Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC）

NCT06431685 Phase 1

Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer

Sichuan University

NCT06326411 Phase 1

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

United States, Austr...

Nested Therapeutics, Inc

NCT06714708 Phase 2

Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC

Anhui Provincial Cancer Hospit...

Imaging-based PRediction of Eligibility for ChemoImmunotherapy in reSEctable NSCLC, iPRECISE

Samsung Medical Center

NCT04665206 Phase 1, Phase 2

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

United States, Austr...

Vivace Therapeutics, Inc

OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)

Belgium, Italy, Neth...

European Organisation for Rese...

NCT05417321 Phase 1, Phase 2

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

United States, China

Shanghai Huaota Biopharmaceuti...

Related Conditions

advanced solid tumor (2) lung cancer (2) low dose radiotherapy (2) solid tumor adult (2) ovarian cancer (1) endometrial cancer (1) nsclc stage iv (1) cancer (1) adenocarcinoma of lung (1) squamous cell lung cancer (1) neoadjuvant therapy (1) pd 1 inhibitor (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology